Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$4.72 USD
-0.45 (-8.70%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $4.73 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
LYRA 4.72 -0.45(-8.70%)
Will LYRA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LYRA
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
Other News for LYRA
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics Announces Board and Committee Changes
Lyra Therapeutics management to meet with Cantor Fitzgerald
Lyra Therapeutics management to meet with Cantor Fitzgerald
Lyra Therapeutics price target lowered by $1 at BofA, here's why